Effects of Herbal Products on Metabolism and Hunger
NCT00198952 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30
Last updated 2005-09-20
Summary
to test safety and efficacy on metabolism, heart rate, blood pressure, TSH (and other blood)and hunger/caloric compensation on ephedra versus placebo
Conditions
- Obesity
- Metabolism
Interventions
- DRUG
-
DietPro
- DRUG
Sponsors & Collaborators
-
Natural Prescriptions
collaborator UNKNOWN -
Johns Hopkins Bloomberg School of Public Health
lead OTHER
Principal Investigators
-
Lawrence J Cheskin, MD · Johns Hopkins Bloomberg School of Public Health
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 50 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2000-02-29
- Completion
- 2001-03-31
Countries
- United States
Study Locations
More Related Trials
-
Determining Metabolic Effects of Valproate and Antipsychotic Therapy
NCT00167934 ·Status: COMPLETED ·Phase: NA
-
The Effects of Antipsychotic Drugs on Brain Metabolism in Healthy Individuals
NCT02536846 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease
NCT02697734 ·Status: COMPLETED ·Phase: PHASE3
-
The Effects of Modafinil to Counteract the Adverse Metabolic Consequences of Sleep Restriction
NCT00895570 ·Status: COMPLETED ·Phase: NA
-
Heart Rate Variability in Response to Metformin Challenge
NCT02500628 ·Status: COMPLETED ·Phase: PHASE2
-
Acute Consequences of Glucocorticoid Secretion in Overweight and Obese Individuals During Maximum Calorie Intake
NCT06556277 ·Status: COMPLETED ·Phase: NA
-
Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome
NCT07247162 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Efficacy of Lifestyle Interventions and Metformin for the Treatment of Antipsychotic-Induced Weight Gain
NCT00451399 ·Status: COMPLETED ·Phase: PHASE4
-
PREDnisolone-induced Beta-cell Dysfunction Prevented by EXenatide
NCT00744224 ·Status: COMPLETED ·Phase: NA
-
Effects of Atypical Antipsychotic and Valproate Combination Therapy on Glucose and Lipid Metabolism in Schizophrenia
NCT00552500 ·Status: COMPLETED ·Phase: NA
-
Monitoring and Management for Metabolic Side Effects of Antipsychotics
NCT01875861 ·Status: COMPLETED ·Phase: NA
-
The Effect of GLP-1 Receptor Activation on Central Reward and Satiety in Obesity and Diabetes
NCT01281228 ·Status: COMPLETED ·Phase: NA
-
Substrate Metabolism and Insulin Sensitivity in Patients With Hyperprolactinemia Before and After Treatment
NCT00699530 ·Status: WITHDRAWN
-
To Investigate Effects GSK561679 on Part of the Body's System That Controls the Balance of Many of the Hormones.
NCT00426608 ·Status: COMPLETED ·Phase: PHASE1
-
Treatment of Antipsychotic-associated Obesity With a GLP-1 Analogue
NCT01794429 ·Status: COMPLETED ·Phase: PHASE3
-
Examining the Effects of CXB722 in Neuroendocrine Stress Response in Healthy Males
NCT00814931 ·Status: COMPLETED ·Phase: PHASE1
-
A Prospective Study to Assess Metabolic Changes in Children and Adolescents Treated With Atypical Antipsychotics
NCT00480168 ·Status: COMPLETED
-
Circadian Clocks and Eating Patterns (Cohort)
NCT04642534 ·Status: COMPLETED
-
Changes in Metabolic Rate and Perceptual Indicators After Acute Ingestion of Paraxanthine
NCT05811923 ·Status: COMPLETED ·Phase: NA
-
Desmopressin Stimulation Test Performance in ACTH-Dependent Cushing Syndrome
NCT06635629 ·Status: RECRUITING ·Phase: PHASE2
-
Examination of Bromocriptine on Homeostatic and Hedonic Mechanisms of Food Intake in Individuals at High Risk for T2DM
NCT05405244 ·Status: COMPLETED ·Phase: PHASE3
-
An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy
NCT00677313 ·Status: COMPLETED ·Phase: NA
-
Anti-psychotic Medication (New Use) Weight Loss Study
NCT01272752 ·Status: WITHDRAWN ·Phase: PHASE2
-
Collecting Information About Treatment Results for Patients With Cushing's Syndrome
NCT03364803 ·Status: RECRUITING
-
Pharmacogenomics of the Variability in the In Vivo Response to Glucocorticoids
NCT03023891 ·Status: COMPLETED ·Phase: PHASE1